肿瘤免疫编辑与免疫治疗

Schreiber等人于2002年提出肿瘤免疫编辑学说。肿瘤免疫编辑分为3个阶段:清除阶段、均衡阶段和逃逸阶段。肿瘤免疫编辑学说较全面的阐释了肿瘤与宿主免疫系统之间的复杂的相互作用。肿瘤免疫编辑学说对肿瘤免疫治疗具有一定的指导意义。依据肿瘤免疫治疗实践,提出了肿瘤免疫编辑和肿瘤免疫治疗的一些观点。     

肺保护策略机械通气的再评价

通常认为急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)患者应用肺保护策略机械通气可降低病死率,主要由于潮气量的降低。对已发表的随机对照研究再次分析,发现平台压与患者病死率明显相关。平台压低于30cmH2O时,潮气量可以在一定范围内增加,不影响患者预后。但选择小潮气量可能对病人有害。随机对照研究在试验设计、统计学分析、病人同质性等方面依然存在很多问题。从现有资料看,潮气量和平台压都很重要。     

非小细胞肺癌的综合诊治策略——NCCN肿瘤学临床实践指南（2006第二版）评析

肺癌目前位于世界肿瘤死亡原因的首位。肺癌的治疗应根据临床不同的分期,选择规范化的治疗方案。肺癌规范化综合治疗可使早期肺癌患者5年生存率达50%~70%左右。中晚期达到25%左右。美国NCCN肿瘤学临床实践指南在2006年发布了第二版非小细胞肺癌治疗方案,对于规范化治疗肺癌以及提高肺癌病人生存率和生存质量有着积极的意义。     

恶性肿瘤患者治疗的知情权

肿瘤微创治疗在本世纪得到飞速发展,有着不可替代的优势。调查结果却显示目前患者及家属对这种治疗方法不太了解。笔者认为医务人员有义务告知恶性肿瘤患者其病情和先进的治疗方法,这有利于患者树立战胜疾病的信心,配合治疗,合理安排自己的生活。     

医护人员对癌症告知态度的调查研究

为了了解医护人员对癌症告知的态度,对634名医护人员进行问卷调查。结果显示,医护人员不十分赞同将真情完全告知患者,其告知意愿在一定程度上取决于患者的知情愿望,他们比较认同家属拥有决策权,且普遍认为患者不是充分知晓病情。因此,医护人员应该增强告知认识,尊重患者告知意愿,引导家属告知观念,努力提高患者知情程度。     

影响乳腺癌诊疗过程的临床决策因素分析

多种因素可以影响乳腺癌的临床决策。本文从四个方面进行探讨,期望探索出适合我国国情的乳腺癌临床诊疗模式。首先,多专科的良好协作是乳腺癌临床决策的前提;其次,陈旧的乳腺癌诊疗观念限制了科学的临床决策;第三,防御性医疗行为降低了乳腺癌临床决策的质量;第四,要考虑到社会心理因素在诊疗决策中的影响。     

癌症患者生存质量研究进展

随着癌症患者生存时间和生存人数的增加,生存者本人和家属更加重视生存质量。本文总结分析近年来国内外癌症患者生存质量的研究状况,以期在癌症治疗过程中,不仅关注躯体功能和疾病本身以及由治疗带来的症状和体征,同时注重心理和社会职能。     

癌症患者人格类型及其与应对策略、社会支持的关系

该研究旨在调查和分析癌症患者人格类型及其与应对策略、社会支持的关系。采用艾森克人格问卷简式量表、社会支持评定量表、医用应对问卷等测查工具对205名癌症病人进行调查。结果显示:1.癌症患者可以聚类为两类人格:温和健康型和身心障碍型;2.身心碍型患者的屈服应对显著高于温和健康型患者;3.身心障碍型患者的客观社会支持和主观社会支持都显著低于温和健康型患者。研究表明,癌症患者可分为温和健康型和身心障碍型两种人格类型。身心障碍型患者采用更多的屈服应对,同时获得的社会支持也更少。     

Distress and Family Functioning in Oncogenetic Counselling for Hereditary and Familial Breast and/or Ovarian Cancers

We conducted a psychological assessment during oncogenetic counseling for hereditary breast/ovarian cancer. Anxiety and depression were assessed with the HAD scale, and family functioning and satisfaction with FACES III. HAD was administered at baseline (t ₁)_, at risk communication (t ₂), at genetic test result communication, or at first surveillance in not tested subjects (t ₃); FACES III was administered at baseline only. We analysed a total of 185 questionnaires administered to the 37 subjects studied. Although not pathological, distress was significantly higher at t ₂ and t ₃ (p = 0.027 and p = 0.039, respectively). Health and marital status were significantly associated with distress. In a disease-free condition, anxiety was higher (p = 0.027) at t _2, and for single status, depression increased from t ₁ to t ₂ (p = 0.026). Families were perceived to be well functioning, and subjects were satisfied with their families. The data collected in this analysis could help to improve the quality of oncogenetic counselling in clinical practice.     

Disclosure of Genetics Research Results after the Death of the Patient Participant: A Qualitative Study of the Impact on Relatives

When a gene mutation is identified in a research study following the death of the study participant, it is not clear whether such information should be made available to relatives. We report here an evaluation of the impact on relatives of being informed of study results that detected pathogenic BRCA2 mutations in a male relative, now deceased, who had early onset (under the age of 55) prostate cancer. The breast and ovarian cancer risk was unknown to the living relatives. Qualitative analysis of interviews with thirteen relatives indicated that those who had a higher risk perception, resulting from an awareness of cancer family history or experiential knowledge of cancer in their family, tended to adjust more easily to the results. All participants believed that genetics research results of clinical significance should be fed back to relatives. Those who were fully aware of the BRCA2 results and implications for themselves felt they had benefited from the information, irrespective of whether or not they had elected for genetic testing, because of the consequent availability of surveillance programs. Initial anxiety upon learning about the BRCA2 result was alleviated by genetic counselling. Factors influencing those who have not engaged with the information included scepticism related to the relative who attempted to inform them, young age and fear of cancer. Those who had not sought genetic counselling did not attempt further dissemination, and some were not undergoing regular screening. Implications for informed consent in genetics research programs, and the requirement for genetic counselling when research results are disclosed, are discussed. Names have been changed to protect the privacy of study participants.